Vir Biotechnology, Inc.
VIR
$9.40
$0.111.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.05% | 25,183.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.05% | 26,595.83% | |||
| Cost of Revenue | 24.14% | -41.60% | |||
| Gross Profit | -350.44% | 83.87% | |||
| SG&A Expenses | -1.17% | 6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.81% | -35.47% | |||
| Operating Income | -177.45% | 72.32% | |||
| Income Before Tax | -191.51% | 73.58% | |||
| Income Tax Expenses | 224.09% | -181.55% | |||
| Earnings from Continuing Operations | -192.84% | 73.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -192.84% | 73.69% | |||
| EBIT | -177.45% | 72.32% | |||
| EBITDA | -189.05% | 73.54% | |||
| EPS Basic | -176.68% | 73.75% | |||
| Normalized Basic EPS | -194.23% | 75.38% | |||
| EPS Diluted | -176.68% | 73.75% | |||
| Normalized Diluted EPS | -194.23% | 75.38% | |||
| Average Basic Shares Outstanding | 5.84% | 0.22% | |||
| Average Diluted Shares Outstanding | 5.84% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||